This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Project Ensuring Quality and Cooperation in the Chronic Obstructive Pulmonary Disease (COPD) Treatment (KOSMOS)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00772733
First received: October 14, 2008
Last updated: February 21, 2011
Last verified: February 2011
October 14, 2008
February 21, 2011
October 2008
December 2010   (Final data collection date for primary outcome measure)
  • Control visits at General practitioners [ Time Frame: 6-12 months ]
  • Lung function measured by spirometry [ Time Frame: 6-12 months ]
Same as current
Complete list of historical versions of study NCT00772733 on ClinicalTrials.gov Archive Site
  • Dyspnoea on MRC scale [ Time Frame: 6-12 months ]
  • Smoking status [ Time Frame: 6-12 months ]
  • Rehabilitation completed in the municipality rehabilitation team [ Time Frame: 6-12 months ]
Same as current
Not Provided
Not Provided
 
A Project Ensuring Quality and Cooperation in the Chronic Obstructive Pulmonary Disease (COPD) Treatment
A Project Ensuring Quality and Cooperation in the Chronic Obstructive Pulmonary Disease (COPD) Treatment
The purpose of this study is to ensure the quality of the COPD treatment in primary care by implementing planned follow-up visits, where the disease condition is evaluated and optimised in accordance with the national COPD recommendations. If relevant the general practitioner (GP) will refer patients to COPD rehabilitation conducted by relevant municipality rehabilitation teams. Secondarily the purpose is to improve collaboration and communication between the local hospital pulmonologist, GPs and the municipality rehabilitation team
Not Provided
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Diagnosed patients with COPD, verified by spirometry in general practise and/or municipalities.
  • COPD
  • Chronic Diseases
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
936
December 2010
December 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • COPD diagnose, verified by spirometry
  • Having given informed consent

Exclusion Criteria:

Sexes Eligible for Study: All
35 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Denmark
 
 
NCT00772733
NIS-RDK-DUM-2007/1
No
Not Provided
Not Provided
Björn.E.Eriksson, MD, VP Medical, AstraZeneca Pharmaceuticals
AstraZeneca
Not Provided
Study Chair: Michael Skov Jensen, MD Region Hospital Viborg, DK
Study Chair: Tina Brandt Sorensen, MD Region Hospital Horsens, DK
Principal Investigator: Ove Grann Aalborg
AstraZeneca
February 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP